The Hetero Ring Has At Least Seven Members Patents (Class 514/450)
-
Patent number: 8178578Abstract: A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal.Type: GrantFiled: December 19, 2007Date of Patent: May 15, 2012Assignee: The University of ManchesterInventors: Timothy William Wallace, David John Edwards, John Anthony Hadfield
-
Publication number: 20120114670Abstract: Disclosed are compositions and methods related to new targets for cancer treatment.Type: ApplicationFiled: January 23, 2011Publication date: May 10, 2012Applicant: UNIVERSITY OF ROCHESTERInventors: Hartmut Land, Helene R. McMurray, Erik R. Sampson
-
Publication number: 20120115862Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1? and/or TNF-?. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.Type: ApplicationFiled: October 9, 2009Publication date: May 10, 2012Inventors: Stefan Laufer, Wolfgang Albrecht
-
Publication number: 20120108545Abstract: Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.Type: ApplicationFiled: May 19, 2010Publication date: May 3, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Gary H. Posner, Lauren E. Woodard, David R. Levine, Deuk Kyu Moon, Bryan T. Mott
-
Publication number: 20120101053Abstract: The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis.Type: ApplicationFiled: June 16, 2010Publication date: April 26, 2012Inventors: Cameron Black, Christian Beaulieu
-
Publication number: 20120093922Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.Type: ApplicationFiled: April 29, 2010Publication date: April 19, 2012Applicant: AMARIN CORPORATION PLCInventors: Mehar Manku, Jonathan Rowe
-
Patent number: 8158623Abstract: The invention discloses a new use of a class of heptacyclic compounds in the preparation of formulations for the prevention and treatment of diabetes and metabolic syndromes; the present invention also discloses a new class of heptacyclic compounds; the present invention also discloses a process for preparing the heptacyclic compounds and a composition containing the same. The heptacyclic compounds of the present invention can be used to effectively preventing or treating diseases such as diabetes and metabolic syndromes.Type: GrantFiled: May 29, 2007Date of Patent: April 17, 2012Assignee: Shanghai Institute of Materia Medica Chinese Academy of SciencesInventors: Jianhua Shen, Ying Leng, Hualiang Jiang, Junhua Chen
-
Publication number: 20120088822Abstract: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.Type: ApplicationFiled: May 6, 2011Publication date: April 12, 2012Applicant: SOMAXON PHARMACEUTICALS, INC.Inventors: Roberta L. Rogowski, Susan E. Dubé, Philip Jochelson, Neil B. Kavey
-
Patent number: 8147806Abstract: The disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.Type: GrantFiled: January 11, 2005Date of Patent: April 3, 2012Assignee: Carnegie Mellon UniversityInventor: Eric T. Ahrens
-
Publication number: 20120077775Abstract: Disclosed are macrocyclic compounds of formulae I-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicants: LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURGInventors: Nicolas WINSSINGER, Sofia BARLUENGA, Martin KARPLUS
-
Publication number: 20120077778Abstract: Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.Type: ApplicationFiled: September 29, 2010Publication date: March 29, 2012Inventors: Andrea Bourdelais, Daniel Baden, Allan Goodman, Steven Fontana
-
Publication number: 20120071547Abstract: The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2.Type: ApplicationFiled: March 15, 2011Publication date: March 22, 2012Applicants: NATIONAL MUSEUM OF MARINE BIOLOGY & AQUARIUM, NATIONAL SUN YAT-SEN UNIVERSITYInventors: JYH-HORNG SHEU, WEI-HSIEN WANG, ZHI-HONG WEN, BO-WEI CHEN, PING-JYUN SUNG
-
Publication number: 20120071539Abstract: Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element. Methods of using such compositions both in therapies involving RNAi-mediated suppression of gene expression, as well as, in vitro methods that allow for the targeted modulation of expression of a polynucleotide of interest are provided. Pharmaceutical or cosmetic compositions comprising such compounds and silencing elements also are disclosed. Methods for screening a compound of interest for the ability to modulate the activity of a heterologous silencing element also are provided.Type: ApplicationFiled: December 12, 2007Publication date: March 22, 2012Applicant: Emory UniversityInventor: Peng Jin
-
Publication number: 20120071548Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.Type: ApplicationFiled: September 21, 2011Publication date: March 22, 2012Applicant: BTG International LimitedInventor: Richard L. Veech
-
Publication number: 20120071549Abstract: The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-?), interleukin-1? (IL-1?), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines.Type: ApplicationFiled: May 24, 2010Publication date: March 22, 2012Applicant: DAEWOO PHARMACEUTICAL IND. CO., LTD.Inventors: Young-Hoon Ji, Dong-Hee Kim, Jae-Seon Kang, Chun-Gyu Kim, Sung-Uk Chung, Sung-Woo Hwang, Kyung-Ran Kang
-
Publication number: 20120071465Abstract: The present invention relates to the compounds useful in the prevention and/or treatment of tumours. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumours presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumour glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention.Type: ApplicationFiled: May 20, 2010Publication date: March 22, 2012Inventors: Virginie Clement, Ivan Radovanovic
-
Patent number: 8138166Abstract: The present invention discloses a method to induce fatty liver in an animal. The steps of the method comprise: feeding an animal with a high calorie diet, and injecting a mitochondrial inhibitor into the animal to inhibit the mitochondrial activity of the animal, then resulting in fat accumulation and inflammation in the liver of the animal.Type: GrantFiled: July 8, 2010Date of Patent: March 20, 2012Assignee: Taipei Medical UniversityInventors: Rong-Hong Hsieh, Sheng-Mei Lin
-
Publication number: 20120065256Abstract: Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.Type: ApplicationFiled: April 5, 2011Publication date: March 15, 2012Applicant: Galderma S.A.Inventors: Alexandre KAOUKHOV, Cecile Cousin
-
Publication number: 20120065257Abstract: The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment and/or prevention of migraine, which includes mono-therapy and alternatively, co-therapy with at least anti-migraine agent.Type: ApplicationFiled: November 21, 2011Publication date: March 15, 2012Inventor: Virginia L. Smith-Swintosky
-
Publication number: 20120059050Abstract: The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R1 and R2 are disclosed in the specification of the present invention, and the derivative of the present invention is a structurally simplified analogue of the gambogic acid compound; wherein the gambogic acid compound possesses anti-cancer characteristics, and could be used for preparation of anti-tumor drugs.Type: ApplicationFiled: November 9, 2010Publication date: March 8, 2012Inventors: Qidong You, Xiaojian Wang, Qian Yang, Na Lu, Changjun Lin, Qinglong Guo
-
Publication number: 20120058178Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.Type: ApplicationFiled: March 30, 2010Publication date: March 8, 2012Applicant: Eisai R&D Management Co., Ltd.Inventors: Hiroshi Kikuchi, Kenji Hyodo, Hiroshi Ishihara
-
Patent number: 8128948Abstract: A composition containing suspensolide and optionally at least one of ?-hydroxy acid of epianastrephin, ?-hydroxy acid of anastrephin, 2,6-dimethyl-6-vinyl-cyclohexeneacetic acid, ?-D-glucopyranosyl 2,6-dimethyl-6-vinyl-cyclohex-1-ene-1-acetoate, or mixtures thereof, and optionally a carrier or carrier material; the composition contains no ?-bisabolene and no ?-farnesene. A method for attracting Anastrepha species (e.g., A. suspensa) involving treating an object or area with an Anastrepha species attracting effective amount of the above composition.Type: GrantFiled: May 15, 2008Date of Patent: March 6, 2012Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Peter E.A. Teal, Spencer S. Walse
-
Patent number: 8129426Abstract: Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have following formula I. It has been proved by pharmacological tests that these compounds and compositions have evident immuno-suppressive activities, and may be used in the preparation of novel immuno-suppressants for treating the diseases caused by hyperfunction of human immunity (e.g. the auto-immune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis and the like), and for inhibiting the graft rejection after cell or organ transplantation.Type: GrantFiled: July 20, 2006Date of Patent: March 6, 2012Assignee: Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Ying Li, Jianping Zuo, Zhongshun Yang, Junxia Wang, Yu Zhang, Wei Tang, Jianxin Zhang
-
Publication number: 20120046296Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.Type: ApplicationFiled: October 31, 2011Publication date: February 23, 2012Inventor: Ute Isele
-
Publication number: 20120040916Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/?-catenin pathway by selecting a subject with a condition mediated by the Wnt/?-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly inhibiting the Wnt/?-catenin pathway in a subject is also disclosed.Type: ApplicationFiled: December 21, 2009Publication date: February 16, 2012Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20120035149Abstract: Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes.Type: ApplicationFiled: December 16, 2009Publication date: February 9, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Qun-Yong Zhou, Jia-Da Li, Qi Huang
-
Publication number: 20120034205Abstract: The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke.Type: ApplicationFiled: July 8, 2011Publication date: February 9, 2012Inventor: Daniel L. Alkon
-
Patent number: 8106221Abstract: The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.Type: GrantFiled: June 20, 2008Date of Patent: January 31, 2012Assignee: Vitae Pharmaceuticals, Inc.Inventors: John J. Baldwin, Salvacion Cacatian, David A. Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Alexey V. Ishchenko, Lanqi Jia, Gerard McGeehan, Robert D. Simpson, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Wei Zhao, Linghang Zhuang
-
Publication number: 20120022150Abstract: A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds.Type: ApplicationFiled: September 1, 2011Publication date: January 26, 2012Applicant: EPIPHARM GMBHInventor: Rosemarie SIFT CARTER
-
Publication number: 20120020948Abstract: The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke.Type: ApplicationFiled: July 8, 2011Publication date: January 26, 2012Inventor: Daniel L. Alkon
-
Publication number: 20120022149Abstract: There are disclosed pharmaceutical compositions, particularly ophthalmic compositions, that contain relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. In a preferred embodiment, the composition is a multi-dose topical aqueous ophthalmic composition that contains relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents.Type: ApplicationFiled: July 20, 2011Publication date: January 26, 2012Inventors: Masood A. Chowhan, Malay Ghosh, Wesley Wehsin Han, Way-Yu Lin, Vincent Nguyen
-
Patent number: 8101653Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.Type: GrantFiled: January 26, 2004Date of Patent: January 24, 2012Assignee: BTG International LimitedInventor: Richard L. Veech
-
Patent number: 8101654Abstract: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops.Type: GrantFiled: July 7, 2006Date of Patent: January 24, 2012Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori
-
Publication number: 20120015922Abstract: Artesunate is a derivative of artemisinin isolated from a Chinese herb Artemisia annua L. It is used clinically for the treatment of malaria. We investigated potential anti-inflammatory actions of artemisinin derivatives. artemisinin derivatives significantly inhibited OVA-induced signs, symptoms and parameter of airway disorders Taken together, our results clearly demonstrate anti-inflammatory effects of artemisinin derivatives. Artemisinin derivatives can be used to complement or to replace oral steroids during asthma exacerbation treatment. Further artemisinin derivatives can be used as an anti-inflammatory agent for controlling airway disorders.Type: ApplicationFiled: March 24, 2010Publication date: January 19, 2012Applicant: NATIONAL UNIVERSITY OF SINGAPOREInventor: Wai Shiu Fred Wong
-
Publication number: 20120015953Abstract: The present invention relates to compositions comprising an antagonist of the histamine H1 receptor and a compatible antagonist of the histamine H4 receptor. The antagonist compounds are selected to prevent the H4 receptor antagonist from interfering with the H1 receptor antagonist's suppression of acute phase allergic responses in a patient. The present invention also relates to compositions comprising a mast cell stabilizer and a compatible antagonist of the histamine H4 receptor.Type: ApplicationFiled: July 14, 2011Publication date: January 19, 2012Inventors: Clay Beauregard, Peter G. Klimko, John M. Yanni, Daniel A. Gamache
-
Patent number: 8097648Abstract: The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.Type: GrantFiled: November 18, 2005Date of Patent: January 17, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Bruce A. Littlefield, Murray J. Towle, Boris M. Seletsky, Melvin J. Yu, Wanjun Zheng
-
Publication number: 20120010278Abstract: In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Inventors: Richard Schlegel, Dan-Paul Hartmann, Astrid Baege
-
Publication number: 20120010277Abstract: Compounds of the avermectin family or derivatives thereof, notably latidectin, are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.Type: ApplicationFiled: April 5, 2011Publication date: January 12, 2012Applicant: Galderma S.A.Inventors: Alexandre KAOUKHOV, Cecile Cousin
-
Publication number: 20120004200Abstract: A topical pharmaceutical composition including, as a pharmaceutical active agent, a water-sensitive compound in a solubilised form in a physiologically acceptable medium is described. A method for preparing such a composition, and uses thereof in dermatology are also described.Type: ApplicationFiled: December 21, 2009Publication date: January 5, 2012Applicant: GALDERMA S.A.Inventors: Karine Nadau-Fourcade, Nathalie Barthez, Laëtitia Mazeau
-
Publication number: 20110319348Abstract: Provided are formulations containing brassinosteroids or their derivatives for treating androgen-associated conditions, such as prostate problems. Particularly formulations comprising at least one brassinosteroid or a derivative thereof are provided for treating benign prostatic hyperplasia or androgenic alopecia.Type: ApplicationFiled: June 2, 2011Publication date: December 29, 2011Applicant: GRASSES OF EDEN LTD.Inventors: Amir Kitron, Rochel Pergamentz
-
Publication number: 20110318412Abstract: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.Type: ApplicationFiled: May 18, 2007Publication date: December 29, 2011Applicant: Somaxon Pharmaceuticals, Inc.Inventors: Luigi Schioppi, Brian T. Dorsey, Michael Skinner, John Carter, Terry Cobb, Neil B. Kavey
-
Patent number: 8084490Abstract: The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.Type: GrantFiled: June 16, 2005Date of Patent: December 27, 2011Assignee: Janssen Pharmaceutica N.V.Inventors: David F. McComsey, Michael H. Parker, Allen B. Reitz, Bruce E. Maryanoff
-
Publication number: 20110306659Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.Type: ApplicationFiled: June 30, 2011Publication date: December 15, 2011Applicant: Novartis AGInventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
-
Publication number: 20110305784Abstract: Disclosed herein are seventeen new compounds and five fractionated products obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds and the five fractionated products have activities in inhibiting the growth of tumor/cancer cells. In addition, the acetone-extracted product of gamboge resin and the five fractionated products obtained therefrom have analgesic and anti-inflammatory effects.Type: ApplicationFiled: May 17, 2011Publication date: December 15, 2011Applicant: Taiwan Sunpan Biotechnology Development Co, Ltd.Inventor: Sen-Bin Lee
-
Publication number: 20110306581Abstract: Perfluorocarbon emulsions having a high stability and good oxygen release are disclosed and described. These perfluorocarbon emulsions are typically for use as artificial oxygen carriers. The perfluorocarbon emulsions include a disperse phase of a perfluorocarbon and an emulsion stabilizer, and continuous phase. The emulsion stabilizer can primarily include a poly(ethylene oxide) block copolymer. These stabilized perfluorocarbon emulsions can be used in liquid and/or hydrogel phases of perfusion bioreactors or various other culture systems to enhance cell viability in thick tissue constructs, or as blood substitutes, although other applications may also be considered.Type: ApplicationFiled: December 8, 2009Publication date: December 15, 2011Applicant: University of Utah Research FoundationInventors: Natalya Y. Rapoport, Glenn D. Prestwich, Russell Morris Condie
-
Publication number: 20110306658Abstract: Disclosed herein are seventeen new compounds obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds have activities in inhibiting the growth of tumor/cancer cells.Type: ApplicationFiled: May 17, 2011Publication date: December 15, 2011Applicant: Taiwan Sunpan Biotechnology Development Co, Ltd.Inventor: Sen-Bin Lee
-
Publication number: 20110300137Abstract: The present application discloses the use of the anti-malarial drug lumefantrine and related compounds in the treatment of cancer.Type: ApplicationFiled: June 1, 2011Publication date: December 8, 2011Inventor: Douglas Tyler McKenzie
-
Publication number: 20110300227Abstract: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.Type: ApplicationFiled: May 20, 2011Publication date: December 8, 2011Applicant: NORTH TEXAS MEDICAL ASSOCIATESInventor: Ivan E. Danhof
-
Publication number: 20110288163Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: June 30, 2011Publication date: November 24, 2011Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Publication number: 20110288022Abstract: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.Type: ApplicationFiled: June 3, 2011Publication date: November 24, 2011Inventors: Miao-Kun Sun, Daniel L. Alkon